The decision comes in the wake of continuing regulatory scrutiny by antitrust regulators in the UK and U.S. over its takeover offer.

Following a continuation of regulatory reviews in the United States and Britain, Roche and Spark Therapeutics announced another extension of their $4.3 billion merger.

Roche’s offer for Spark is now valid upto September 3, said while adding that the terms and conditions of its offer remain unchanged.

“The parties remain committed to the transaction and are working cooperatively and expeditiously with the Federal Trade Commission and UK Competition and Markets Authority,” said Roche.

Categories: Creativity, Entrepreneurship, HR & Organization, Regulations & Legal, Strategy

Tags: Britain, Competition and Markets Authority, extension, Federal Trade Commission, gene therapy, healthcare, M&A, merger, mergers and acquisition, regulatory, reviews, Roche, Spark Therapeutics, U.S, UK, United States